ArticleAmerican journal of cancer research2026
Clinical value of serum osteocalcin (N-MID) combined with thyroid transcription factor-1 for predicting bone metastasis of lung cancer.
Article in American journal of cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the clinical predictive value of combining N-terminal serum osteocalcin (N-MID) with thyroid transcription factor-1 (TTF-1) for bone metastasis in lung cancer. This retrospective analysis included 147 lung cancer patients admitted to the hospital between February 2020 and October 2024. Patients were divided into a bone metastasis group (n=83) and a non-bone metastasis group (n=64) based on the presence of bone metastases. Baseline clinical data and laboratory parameters, including TTF-1, N-MID, tumor abnormal protein (TAP), parathyroid hormone (PTH), vascular endothelial growth factor (VEGF), total N-terminal propeptide of type I collagen (tPINP), and β-C-terminal telopeptide of type I collagen (β-CTX) were collected. Univariate and multivariate logistic regression analyses were performed to identify independent risk factors for bone metastasis. Model performance was evaluated using receiver operating characteristic (ROC) curves, integrated discrimination improvement (IDI), category-based net reclassification improvement (cNRI), the Hosmer-Lemeshow goodness-of-fit test, and decision curve analysis (DCA). Age-stratified analysis and external validation were further conducted to ensure the generalizability of study. Univariate analysis showed that TTF-1 positivity rate and the levels of TAP, PTH, VEGF, tPINP, β-CTX, and N-MID were significantly higher in the bone metastasis group than in the non-bone metastasis group (all
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.